BCAB - Bioatla Inc

-

$undefined

N/A

(N/A)

Bioatla Inc NasdaqGM:BCAB BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Location: 11085 Torreyana Road, San Diego, CA, 92121, United States | Website: https://www.bioatla.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-8.968M

Cash

32.36M

Avg Qtr Burn

-14.35M

Short % of Float

9.90%

Insider Ownership

10.90%

Institutional Own.

32.92%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

Phase 2

Data readout

Ozuriftamab vedotin (BA3021) (CAB-ROR2-ADC) Details
Head and neck squamous cell carcinoma

Phase 2

Update

mecbotamab vedotin (BA3011) (anti-AXL ADC) Details
Solid tumor/s, Soft tissue sarcoma, Non-small cell lung carcinoma, Bone sarcoma, Cancer

Phase 2

Update

Phase 1/2

Data readout

Phase 1/2

Update